Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)‘s stock had its “buy” rating reaffirmed by investment analysts at Guggenheim in a report issued on Wednesday. They currently have a $80.00 price objective on the stock. Guggenheim’s price objective would suggest a potential upside of 76.76% from the stock’s previous close.
A number of other research firms have also weighed in on TEVA. Mizuho reissued a “buy” rating and set a $70.00 target price (down from $75.00) on shares of Teva Pharmaceutical Industries in a report on Friday, August 5th. Goldman Sachs Group Inc. lowered Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $70.00 to $60.00 in a report on Friday, July 15th. Leerink Swann reissued an “outperform” rating and set a $66.00 target price on shares of Teva Pharmaceutical Industries in a report on Tuesday, August 16th. Jefferies Group decreased their target price on Teva Pharmaceutical Industries from $72.00 to $69.00 and set a “buy” rating on the stock in a report on Thursday, July 14th. Finally, Oppenheimer Holdings Inc. decreased their price objective on Teva Pharmaceutical Industries from $77.00 to $72.00 and set an “outperform” rating on the stock in a report on Thursday, July 14th. Seven investment analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $67.14.
Shares of Teva Pharmaceutical Industries (NYSE:TEVA) traded down 0.55% on Wednesday, hitting $45.01. The company’s stock had a trading volume of 2,669,844 shares. Teva Pharmaceutical Industries has a 52 week low of $44.92 and a 52 week high of $66.55. The firm has a market cap of $41.14 billion, a price-to-earnings ratio of 30.07 and a beta of 0.74. The stock’s 50-day moving average price is $50.75 and its 200-day moving average price is $52.69.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.05. The business had revenue of $5 billion for the quarter, compared to analyst estimates of $4.86 billion. Teva Pharmaceutical Industries had a return on equity of 17.77% and a net margin of 7.56%. The firm’s revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.43 EPS. Equities analysts expect that Teva Pharmaceutical Industries will post $5.26 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Monday, August 22nd were paid a dividend of $0.34 per share. The ex-dividend date was Thursday, August 18th. This represents a $1.36 annualized dividend and a yield of 3.00%. Teva Pharmaceutical Industries’s dividend payout ratio is currently 77.85%.
A number of large investors have recently added to or reduced their stakes in the company. Teachers Advisors Inc. boosted its stake in Teva Pharmaceutical Industries by 182.9% in the first quarter. Teachers Advisors Inc. now owns 614,909 shares of the company’s stock valued at $32,904,000 after buying an additional 397,583 shares in the last quarter. Stratos Wealth Partners LTD. boosted its stake in Teva Pharmaceutical Industries by 15.1% in the first quarter. Stratos Wealth Partners LTD. now owns 4,500 shares of the company’s stock valued at $241,000 after buying an additional 592 shares in the last quarter. Howard Hughes Medical Institute boosted its stake in Teva Pharmaceutical Industries by 202.9% in the first quarter. Howard Hughes Medical Institute now owns 35,149 shares of the company’s stock valued at $1,881,000 after buying an additional 23,544 shares in the last quarter. Tobam boosted its stake in Teva Pharmaceutical Industries by 153.7% in the first quarter. Tobam now owns 580,746 shares of the company’s stock valued at $31,075,000 after buying an additional 351,854 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV boosted its stake in Teva Pharmaceutical Industries by 1,127.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,210 shares of the company’s stock valued at $118,000 after buying an additional 2,030 shares in the last quarter. 63.35% of the stock is owned by institutional investors and hedge funds.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.
Receive News & Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.